MX2022001820A - Sal y forma cristalina de un compuesto que tiene actividad agonista para el receptor 5 de esfingosina-1-fosfato [acido (2s,3r,4e)-2-amino-3-hidroxioctadeca-4-enil-1-fosforico (s1p5). - Google Patents

Sal y forma cristalina de un compuesto que tiene actividad agonista para el receptor 5 de esfingosina-1-fosfato [acido (2s,3r,4e)-2-amino-3-hidroxioctadeca-4-enil-1-fosforico (s1p5).

Info

Publication number
MX2022001820A
MX2022001820A MX2022001820A MX2022001820A MX2022001820A MX 2022001820 A MX2022001820 A MX 2022001820A MX 2022001820 A MX2022001820 A MX 2022001820A MX 2022001820 A MX2022001820 A MX 2022001820A MX 2022001820 A MX2022001820 A MX 2022001820A
Authority
MX
Mexico
Prior art keywords
compound
agonistic activity
receptor
salt
crystal form
Prior art date
Application number
MX2022001820A
Other languages
English (en)
Inventor
Stephan D Parent
Melanie Janelle Bevill
Hideomi Kijima
Takayuki Fujito
Courtney S Johnson
Shuhei Otani
Naoko Imura
Travis Lee Houston
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of MX2022001820A publication Critical patent/MX2022001820A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un objeto de la presente invención es proporcionar un compuesto con un equilibrio mejorado de la actividad agonista para los receptores S1P5 en relación con los receptores, y una forma adecuada para las sustancias farmacológicas de los productos farmacéuticos. Se proporciona el Compuesto I que tiene una alta actividad agonista selectiva del receptor S1P5 sobre el receptor S1P1. Además, las formas cristalinas del Compuesto I, las sales del Compuesto I, y las formas cristalinas de las sales del mismo descritas en la presente invención se proporcionan como sustancias farmacológicas de productos farmacéuticos.
MX2022001820A 2019-08-20 2020-08-19 Sal y forma cristalina de un compuesto que tiene actividad agonista para el receptor 5 de esfingosina-1-fosfato [acido (2s,3r,4e)-2-amino-3-hidroxioctadeca-4-enil-1-fosforico (s1p5). MX2022001820A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962889091P 2019-08-20 2019-08-20
PCT/JP2020/031326 WO2021033729A1 (ja) 2019-08-20 2020-08-19 Ｓ１ｐ５受容体作動活性を有する化合物の塩および結晶形

Publications (1)

Publication Number Publication Date
MX2022001820A true MX2022001820A (es) 2022-03-17

Family

ID=74660224

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001820A MX2022001820A (es) 2019-08-20 2020-08-19 Sal y forma cristalina de un compuesto que tiene actividad agonista para el receptor 5 de esfingosina-1-fosfato [acido (2s,3r,4e)-2-amino-3-hidroxioctadeca-4-enil-1-fosforico (s1p5).

Country Status (13)

Country Link
US (1) US20220289675A1 (es)
EP (1) EP4019496B1 (es)
JP (1) JP7409383B2 (es)
KR (1) KR20220050886A (es)
CN (1) CN114302873A (es)
AU (1) AU2020334489A1 (es)
BR (1) BR112022002632A2 (es)
CA (1) CA3150303A1 (es)
IL (1) IL290432A (es)
MX (1) MX2022001820A (es)
TW (1) TW202114984A (es)
WO (1) WO2021033729A1 (es)
ZA (1) ZA202201784B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4355729A1 (en) 2021-06-16 2024-04-24 Celgene Corporation Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases
WO2024129948A1 (en) * 2022-12-16 2024-06-20 Celgene Corporation Heterocyclic compounds as modulators of s1p5

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ234564A (en) * 1986-11-21 1991-04-26 Haessle Ab 1-substituted benzimidazoles and pharmaceutical compositions
GB8725118D0 (en) * 1987-10-27 1987-12-02 Ciba Geigy Ag Rifamycin derivatives
JP2005020882A (ja) 2003-06-25 2005-01-20 Matsushita Electric Works Ltd モータアクチュエータ装置
JP2006064757A (ja) 2004-08-24 2006-03-09 Systec Kyowa:Kk ディスプレイ固定用スタンド
EP2371811B1 (en) * 2004-12-13 2014-10-08 Ono Pharmaceutical Co., Ltd. Azetidinecarboxylic acid derivative and medicinal use thereof
KR20090015968A (ko) * 2006-06-12 2009-02-12 노파르티스 아게 Ｎ-히드록시-3-[4-[[[2-(2-메틸-1ｈ-인돌-3-일)에틸]아미노]메틸]페닐]-2ｅ-2-프로펜아미드의 동질이상체
WO2016088834A1 (ja) * 2014-12-04 2016-06-09 小野薬品工業株式会社 ジヒドロナフタレン誘導体
TWI789495B (zh) * 2018-02-22 2023-01-11 日商小野藥品工業股份有限公司 具有ｓ1ｐ5受體作動活性的化合物

Also Published As

Publication number Publication date
KR20220050886A (ko) 2022-04-25
JP7409383B2 (ja) 2024-01-09
TW202114984A (zh) 2021-04-16
ZA202201784B (en) 2024-02-28
EP4019496A1 (en) 2022-06-29
EP4019496B1 (en) 2024-06-05
AU2020334489A1 (en) 2022-03-03
IL290432A (en) 2022-04-01
WO2021033729A1 (ja) 2021-02-25
JPWO2021033729A1 (es) 2021-02-25
EP4019496A4 (en) 2023-01-11
CA3150303A1 (en) 2021-02-25
CN114302873A (zh) 2022-04-08
US20220289675A1 (en) 2022-09-15
BR112022002632A2 (pt) 2022-05-03

Similar Documents

Publication Publication Date Title
MX2021012542A (es) Proceso para la preparacion de derivados de oxadiazol microbiocidas.
JOP20220155A1 (ar) مشتقات البيرازول مفيدة كعوامل مضادة للسرطان
MX2021006908A (es) Compuesto agonista del receptor thrb y metodo de preparacion y uso del mismo.
MX2022001820A (es) Sal y forma cristalina de un compuesto que tiene actividad agonista para el receptor 5 de esfingosina-1-fosfato [acido (2s,3r,4e)-2-amino-3-hidroxioctadeca-4-enil-1-fosforico (s1p5).
NZ764304A (en) Novel bradykinin b2 receptor antagonists
PH12016502539A1 (en) Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
EA201391662A1 (ru) Соединения с активностью антагонистов мускариновых рецепторов и агонистов адренергического рецептора бета2
EA201590873A1 (ru) Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета2 адренергических рецепторов
MX2021006969A (es) Ligante peptidico.
ZA202208051B (en) Protein degradation agent compound preparation method and application
BR112021026397A2 (pt) Antagonista de ep2
DE602005017162D1 (de) 3-arylthioindol-2-carbonsäureamidderivate und ihre analoge als hemmer von caseinkinase i
PH12021550549A1 (en) Dp antagonist
MY162554A (en) Novel benzamide derivatives
MX2021009971A (es) Compuesto heterociclico, composicion farmaceutica que lo comprende, metodo para su preparacion, y uso de estos.
MX2020008929A (es) Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados y su uso farmaceutico.
JOP20200327A1 (ar) مركبات سيانوتريازول واستخداماتها
MX2022004213A (es) Derivados de 2-azaspiro[3.4]octano como agonistas de m4.
MX2022004215A (es) Derivados de 2-azaespiro[3.4]octano como agonistas de m4.
PH12020550763A1 (en) Pyridinone derivatives and their use as selective alk-2 inhibitors
WO2021094832A8 (en) Heterocyclic nmda antagonists
WO2019022235A9 (ja) 円形脱毛症の治療剤又は予防剤
MY160963A (en) Sustained-release therapeutic agent for hypertension and renal dysfunction
MX2022003830A (es) Compuesto de n-(1h-imidazol-2-il)benzamida y composicion farmaceutica que comprende el mismo como ingrediente activo.
MX2023006696A (es) Composiciones farmaceuticas que comprenden un agonista cannabinoide.